452 related articles for article (PubMed ID: 24262922)
1. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
Chen SF; Kuo HC
J Formos Med Assoc; 2015 Jul; 114(7):583-9. PubMed ID: 24262922
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
Chen CY; Liao CH; Kuo HC
Spinal Cord; 2011 May; 49(5):659-64. PubMed ID: 21243000
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries.
Kuo HC; Liu SH
Neurourol Urodyn; 2011 Nov; 30(8):1541-5. PubMed ID: 21717505
[TBL] [Abstract][Full Text] [Related]
6. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
Chen SF; Chang CH; Kuo HC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Kuo HC
Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
11. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravesical botulinum neurotoxin-A injection on detrusor hyperreflexia in spinal cord injured patients.
Ge XT; Li YF; Wang Q; Zhao JN
Drug Res (Stuttg); 2015 Jun; 65(6):327-31. PubMed ID: 25350080
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia.
Kuo HC
Int J Clin Pract; 2013 Oct; 67(10):1044-9. PubMed ID: 24073977
[TBL] [Abstract][Full Text] [Related]
16. Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.
Lin CC; Kuo HC
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051024
[TBL] [Abstract][Full Text] [Related]
17. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
Chen G; Liao L
Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
19. Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury.
Fougere RJ; Currie KD; Nigro MK; Stothers L; Rapoport D; Krassioukov AV
J Neurotrauma; 2016 Sep; 33(18):1651-7. PubMed ID: 26980078
[TBL] [Abstract][Full Text] [Related]
20. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]